AAA announces Ph3 NETTER-2 study with Lutathera as 1st Line in advanced GEP-NET

(Advanced Accelerator Applications) Advanced Accelerator Applications S.A. (AAA), a Novartis company, today announced that the first patient has been treated in the NETTER-2 Phase III clinical study investigating Lutathera® (USAN: lutetium Lu 177 dotatate / INN: lutetium (177Lu) oxodotreotide) given as first-line treatment, for Grade 2 and Grade 3 advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in combination with long-acting octreotide.